Celgene Corporation
Updated Data from Randomized Controlled Phase II Study Evaluating Oral Apremilast in Psoriatic Arthritis Demonstrates Sustained Response at Six Months
Published in Medical Letter on the CDC and FDA, November 8th, 2009
Apremilast is an oral pluripotent immunomodulator that inhibits the activity of PDE4 and modulates the production of multiple pro-inflammatory mediators, including TNF-a, IL-2 IL-10, IL-17, and IL-23.
CC-10004-PSA-001 sought to determine the efficacy and safety of apremilast in 204 patients at two different dosing...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- World Journal of Gastroenterology
Which is promising as therapeutic targets in patients with biliary tract cancer? EGFR or HER2? - Aeolus Pharmaceuticals, Inc.
Aeolus Drug Protects the Gastrointestinal Tract in Acute Radiation Syndrome Studies Sponsored by the National Institutes of Health's National Institute for Allergy and Infectious Diseases - Biotechnology Business
Cephalon Notified of Generic Filing for Armodafinil Tablets - CardiacAssist Inc.
Privately held CardiacAssist reports record revenues for nine-month financial results - Celgene Corporation
Celgene Reports Record Third Quarter 2009 Operating and Financial Results - Drug Development
Reports from University of California describe recent advances in drug development - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
